Cellares’ Cell Shuttle Platform Accepted into FDA’s Inaugural Manufacturing PreCheck Cohort, First and Only Cell Therapy Platform to Receive Designation

July 5, 2026

BioSpace USA

Overview

Cellares announced its acceptance into the FDA’s inaugural ‘Manufacturing PreCheck Pilot Program,’ as the sole cell therapy platform among seven companies nationwide. Its automated, end-to-end Cell Shuttle platform holds an Advanced Manufacturing Technology (AMT) designation from the FDA and has already secured an IND amendment approval. Participation in this program allows Cellares early and continuous engagement with the FDA, significantly accelerating the regulatory pathway for commercial-scale cell therapy manufacturing.

In Depth

Key Findings

Cellares has announced its selection as the only cell therapy platform provider to be included in the U.S. Food and Drug Administration’s (FDA) newly launched ‘Manufacturing PreCheck Pilot Program.’ This acceptance highlights the FDA’s recognition of the innovative nature and regulatory readiness of Cellares’ automated, end-to-end cell therapy manufacturing platform, the Cell Shuttle. The Cell Shuttle has already been granted an Advanced Manufacturing Technology (AMT) designation by the FDA, and its inclusion in this program is expected to substantially expedite the regulatory review process for commercialization.

Technical & Clinical Details

The Cellares Cell Shuttle is a proprietary, automated, and closed-system platform designed to execute the entire cell therapy manufacturing process. This system offers significant advantages over traditional open, manual processes, including dramatically improved product consistency, reproducibility, quality, and scalability. By reducing contamination risks and minimizing human error, it enhances the safety and efficiency of delivering cell therapy products to patients. The FDA’s Manufacturing PreCheck program aims to facilitate the rapid adoption of advanced manufacturing technologies, enabling Cellares to collaborate closely with the FDA from the early stages of process design. This proactive engagement will help identify and resolve potential regulatory challenges, thereby streamlining future Biologics License Application (BLA) reviews.

Background & Context

While the cell and gene therapy sector offers groundbreaking treatments, it faces persistent challenges related to manufacturing complexity, high costs, and scalability. The increasing demand for personalized cell therapies further exacerbates these issues, making manufacturing automation and standardization critical for successful commercialization. The FDA’s Manufacturing PreCheck program was established to address these industry needs, and Cellares’ selection signifies a formal recognition by regulatory authorities of automated manufacturing solutions as the future direction for the industry. This represents a pivotal moment in shaping the future of cell therapy manufacturing.

Strategic Significance & Outlook

Cellares’ participation in the Manufacturing PreCheck program underscores the technical superiority of the Cell Shuttle platform and its potential to accelerate the market entry of cell therapy products. Insights gained through this collaborative framework with the FDA are likely to contribute to the optimization of manufacturing standards and regulatory pathways across the broader cell therapy industry. The company anticipates several major cell therapy pipelines transitioning to commercialization phases in the coming years, with the Cell Shuttle aiming to play a central role as a manufacturing partner. This development is expected to lead to reduced costs and improved supply stability for cell therapy products, ultimately enhancing patient access to these transformative treatments worldwide.

Source: https://www.biospace.com/press-releases/cellares-accepted-to-fdas-inaugural-manufacturing-precheck-cohort-the-only-cell-therapy-platform-among-seven-companies-nationwide

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.